このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

GEP-NET患者におけるルテチウム[177Lu]オキソドトレオチド注射とオクトレオチドLARによる治療を比較した研究

2026年11月9日 更新者:Sinotau Pharmaceutical Group

手術不能、進行性、高分化型、ソマトスタチン受容体陽性の胃腸膵臓神経内分泌腫瘍患者におけるルテチウム[177Lu]オキソドトレオチド注射による治療とオクトレオチドLARとの治療を比較した研究

This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium[177Lu] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

After the screening period, participants who signed the ICF and were eligible for the study in accordance with the entry criteria were randomly assigned to treatment either Lutetium[177Lu] Oxodotreotide Injection or Octreotide LAR. Participant randomization was performed according to a centralized permuted block randomization scheme with a balanced ratio (1:1) between the 2 treatment groups, stratified by primary site of tumor (pancreatic or non-pancreatic), NET pathological grading (G1 or G2) and by the length of time that a participant was on a constant dose of Octreotide (=< 6 versus > 6 months). Objective tumor assessment in both groups was performed every 12+/-1 weeks from the randomization date according to RECIST Criteria until progression was centrally confirmed: any participants with progressive disease ceased the treatment/assessment period and proceeded to the long-term follow-up period for evaluation of survival and long-term safety.

研究の種類

介入

入学 (実際)

196

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100853
        • Chinese PLA General Hospital
    • Fujian
      • Fuzhou、Fujian、中国、350005
        • The First Afilliated Hospital of Fujian Medical University
      • Xiamen、Fujian、中国、361003
        • The First Affiliated Hospital of Xiamen University
    • Guangdong
      • Guangzhou、Guangdong、中国、510080
        • The First Affiliated Hospital of Sun Yat-sen University
      • Guangzhou、Guangdong、中国、510630
        • The First Affiliated Hospital of Jinan University
    • Henan
      • Zhengzhou、Henan、中国、450052
        • The First Affiliated Hospital of Zhengzhou University
      • Zhengzhou、Henan、中国、450003
        • Henan Provincial People's Hospital
    • Hubei
      • Wuhan、Hubei、中国、430030
        • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
      • Wuhan、Hubei、中国、430022
        • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    • Jiangsu
      • Nanjing、Jiangsu、中国、210006
        • Nanjing First Hospital
    • Jilin
      • Changchun、Jilin、中国、130021
        • The first hospital of Jilin University
    • Shaanxi
      • Xi'an、Shaanxi、中国、710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
      • Xi'an、Shaanxi、中国、710032
        • The First Affiliated Hospital of AFMU
    • Shandong
      • Jinan、Shandong、中国、250012
        • Qilu Hospital of Shandong University
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200032
        • Fudan University Shanghai Cancer Center
      • Shanghai、Shanghai Municipality、中国、200032
        • Zhongshan Hospital, Fudan University
    • Shanxi
      • Taiyuan、Shanxi、中国、030012
        • The First Affiliated Hospital of Shanxi Medical University
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • West China Hospital of Sichuan University
      • Luzhou、Sichuan、中国、646000
        • Affiliated Hospital of Southwest Medical University
      • Mianyang、Sichuan、中国、621099
        • Mianyang Central Hospital
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300060
        • Tianjin Medical University Cancer Institute & Hospital
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310022
        • Zhejiang Cancer Hospital
      • Hangzhou、Zhejiang、中国、310003
        • The First Affiliated Hospital, Zhejiang University School of Medicine

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Ability to understand and willingness to sign a written informed consent document.
  2. Aged 18 years or older.
  3. Histopathologically confirmed low and moderate grade (G1 or G2) unresectable locally advanced or metastatic GEP-NET (based on the fifth edition of the WHO classification and grading criteria for neuroendocrine tumors of the digestive system in 2019, to be centrally confirmed).
  4. Previously received fixed-dose Octreotide LAR (20-30 mg/3-4 weeks) for at least 12 weeks of continuous treatment with disease progression.
  5. Presence of disease progression prior to randomization (time point of disease progression limited to 1 year prior to randomization and no other antitumor therapy received after progression).
  6. Presence of at least 1 measurable site of disease (based on RECIST 1.1).
  7. All target lesions (based on RECIST 1.1) at baseline must be confirmed as somatostatin receptor positive by 68Ga-Dotatate PET/CT .
  8. ECOG score of 0 or 1.
  9. Subjects of childbearing potential voluntarily use an effective method of contraception, such as condoms, oral or injectable contraceptives, IUDs, etc., during treatment and within 4 months (men) or 7 months (women) of the last use of the trial drug.

Exclusion Criteria:

  1. Serum creatinine >150 μmol/L (1.7 mg/dL) or creatinine clearance <50 ml/min (Cockcroft Gault formula).
  2. Hemoglobin <80g/L, or white blood cell count <2.0×10^9/L, or platelets <75×10^9/L.
  3. Serum total bilirubin > 3 × upper limit of normal (ULN).
  4. Serum albumin <30g/L.
  5. alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5×ULN.
  6. international normalized ratio (INR) > 1.5 or partially activated prothrombin time (APTT) > 1.5 x ULN.
  7. Positive human immunodeficiency virus (HIV) antibody.
  8. Positive for hepatitis B virus (HBV) surface antigen (HBsAg) and positive for HBV DNA (≥1×10^4 copies/ml or judged positive by research center criteria), or positive for hepatitis C virus (HCV) antibodies.
  9. Pregnant or lactating females.
  10. Received peptide receptor radionuclide therapy(PRRT) prior to randomization.
  11. Received Octreotide LAR at a dose strength >30 mg/3-4 weeks (increasing dose or frequency) within 12 weeks prior to randomization.
  12. Any patient receiving treatment with short-acting Octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of Lutetium[177Lu] Oxodotreotide Injection, or any patient receiving treatment with Octreotide LAR, which cannot be interrupted for at least 6 weeks before the administration of Lutetium[177Lu] Oxodotreotide Injection.
  13. Received systemic antitumor therapy such as targeted therapy, immunotherapy, antitumor herbal therapy, chemotherapy within 4 weeks prior to randomization.
  14. Participated in other drug clinical trials within 4 weeks prior to randomization and received treatment with the corresponding trial drug.
  15. Received the following treatments within 12 weeks prior to randomization, including but not limited to surgery (except biopsy), radical radiotherapy, hepatic artery interventional embolization, cryoablation of liver metastases, or radiofrequency ablation.
  16. Received external beam radiation therapy for bone metastases within 2 weeks prior to randomization
  17. Toxicity of prior antitumor therapy has not returned to ≤ grade 1 levels (except for alopecia)
  18. Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrollment in the study.
  19. Uncontrolled congestive heart failure, including baseline left ventricular ejection fraction (LVEF) <50%.
  20. uncontrolled diabetes mellitus, including baseline fasting glucose > 2 x ULN.
  21. Any clinically significant active infection.
  22. Known other malignancies (except for those without recurrence within 5 years after adequate treatment)
  23. Known hypersensitivity to Lutetium[177Lu] Oxodotreotide Injection or oxytetracycline acetate microsphere components and their excipients.
  24. Known to be unsuitable for enhanced CT or MRI contrast imaging due to allergic reaction or renal insufficiency.
  25. Any other disease, mental status or surgical condition that is uncontrolled, may interfere with study completion (including poor compliance) or is inappropriate for the use of the investigational drug.
  26. Other treatment options (e.g., chemotherapy, targeted therapy) that, in the opinion of the investigator, are more appropriate for the patient than the treatment provided in the study based on the patient's disease characteristics, i.e., the investigational drug is not the best therapeutic agent for clinical practice.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Lutetium[177Lu] Oxodotreotide Injection

Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) Lutetium[177Lu] Oxodotreotide Injection: Four administrations of 7.4 GBq (200 mCi).

Concomitant amino acids were given with each administration for kidney protection.

Lutetium[177Lu] Oxodotreotide Injection was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.

In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed.

Four administrations of 7.4 GBq (200 mCi) Lutetium[177Lu] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.

他の名前:
  • 177Lu-DOTA0-Tyr3-オクトレオテート
アクティブコンパレータ:Octreotide LAR

60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.

In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed.

60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.

他の名前:
  • サンドスタチンLAR、オクトレオチド

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Progression Free Survival (PFS) assessed by BIRC
時間枠:From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

Progression Free Survival (PFS) was defined as the time from randomization to documented centrally assessed disease progression, as evaluated by the Blinded Independent Review Committee (BIRC), or death due to any cause. If a participant had no centrally assessed progression and had not died at the time of the primary endpoint analysis, the participant was regarded as censored in the context of a time to event analysis at the date of last evaluable tumor assessment. Disease progression was determined by objective tumor response status using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1).

From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Progression Free Survival (PFS) assessed by investigator
時間枠:From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

Progression Free Survival (PFS) was defined as the time from randomization to documented investigator-assessed disease progression, or death due to any cause. If a participant had no investigator-assessed progression and had not died at the time of the primary endpoint analysis, the participant was regarded as censored in the context of a time to event analysis at the date of last evaluable tumor assessment. Disease progression was determined by objective tumor response status using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1).

From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Objective Response Rate (ORR) assessed by investigator
時間枠:From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

Objective Response Rate (ORR) was calculated as the proportion of patients with tumour size reduction (sum of partial responses (PR) and complete responses (CR)) and assessed by investigator according to RECIST 1.1.

From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Objective Response Rate (ORR) assessed by BIRC
時間枠:From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

Objective Response Rate (ORR) was calculated as the proportion of patients with tumour size reduction (sum of partial responses (PR) and complete responses (CR)) assessed by BIRC according to RECIST 1.1.

From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Duration of Response (DoR) assessed by investigator
時間枠:From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

The Duration of Response (DoR) was defined as the time from initially meeting the criteria for response (CR or PR) until the time of progression and assessed by investigator according to RECIST 1.1.

From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Duration of Response (DoR) assessed by BIRC
時間枠:From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

The Duration of Response (DoR) was defined as the time from initially meeting the criteria for response (CR or PR) until the time of progression assessed by BIRC according to RECIST v1.1.

From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Time to Tumour Progression (TTP) assessed by investigator
時間枠:From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

Time to Tumour Progression (TTP) was defined as the time from randomization to progression assessed by investigator. It included patients who dropped out due to toxicity, but omitted patients who died without measured progression (censored to last follow-up date or death date).

From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Time to Tumour Progression (TTP) assessed by BIRC
時間枠:From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

Time to Tumour Progression (TTP) was defined as the time from randomization to progression assessed by BIRC. It included patients who dropped out due to toxicity, but omitted patients who died without measured progression (censored to last follow-up date or death date).

From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Disease Control Rate (DCR) assessed by investigator
時間枠:From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

DCR is defined as the incidence of complete response, partial response and stable disease assessed by investigator according to RECIST v1.1.

From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Disease Control Rate (DCR) assessed by BIRC
時間枠:From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

DCR is defined as the incidence of complete response, partial response and stable disease assessed by BIRC according to RECIST v1.1.

From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
20-month Progression-Free Survival rate assessed by BIRC
時間枠:From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

20-month Progression-Free Survival rate was defined as the proportion of patients whose time from randomization to disease progression by BIRC according to RECIST v1.1 or death exceeds 20 months.

From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
20-month Progression-Free Survival rate assessed by investigator
時間枠:From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

20-month Progression-Free Survival rate was defined as the proportion of patients whose time from randomization to disease progression by investigator according to RECIST v1.1 or death exceeds 20 months.

From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Overall Survival (OS)
時間枠:From date of randomization until date of death from any cause up to final safety cut-off date reached,assessed up to approximately 60 months

Overall Survival (OS) was defined as the time from the date of randomization to the date of death due to any cause or the date of last contact (censored observation) prior to the date of the data cut-off, and during the entire study period (i.e. the treatment period plus follow-up).

From date of randomization until date of death from any cause up to final safety cut-off date reached,assessed up to approximately 60 months
Change From Baseline in the EORTC QLQ-C30 Questionnaire
時間枠:From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

The Quality of Life Questionnaire C30 (QLQ-C30) was developed by the European Organization for Research and Treatment of Cancer (EORTC) to assess quality of life in cancer patients. It includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality-of-life and financial impact. Subjects respond on a four-point scale from "not at all" to "very much" for most items. Raw scores are linearly transformed so each score ranged a 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).

From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Change From Baseline in the EORTC Quality of Life Questionnaire - Neuroendocrine Carcinoid Module (EORTC QLQ-GINET21)
時間枠:From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months

The Quality of Life GI Neuroendocrine Tumor survey (QLQ GINET21) contains a total of 21 items: four single-item assessments relating to muscle and/or bone pain (MBP), body image (BI), information (INF) and sexual functioning (SX), together with 17 items organized into five proposed scales: endocrine symptoms (ED; three items), GI symptoms (GI; five items), treatment-related symptoms (TR; three items), social functioning (SF) and disease-related worries (DRW; three items). The response format of the questionnaire is a four-point Likert scale. Responses are linearly transformed to a 0-100 scale using EORTC guidelines, with higher scores reflecting more severe symptoms.

From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Number of Participants With Adverse Events
時間枠:From informed consent signature through study completion reached at final safety cutoff date,assessed up to approximately 60 months

The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs), Serious Adverse Event (SAEs) and Deaths, through the monitoring of relevant clinical and laboratory safety parameters.

From informed consent signature through study completion reached at final safety cutoff date,assessed up to approximately 60 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jianming Xu、Chinese PLA General Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年8月31日

一次修了 (実際)

2025年6月26日

研究の完了 (実際)

2026年4月3日

試験登録日

最初に提出

2022年7月5日

QC基準を満たした最初の提出物

2022年7月11日

最初の投稿 (実際)

2022年7月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • XT-XTR008-3-01

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。